The clinical behavior of prostate cancer (PCa) is variable, and while the majority of cases remain indolent, 10% of patients progress to deadly forms of the disease. Current clinical predictors used at the time of diagnosis have limitations to accurately establish progression risk. Here we describe the development of a tumor suppressor regulated, cell-cycle gene expression based prognostic signature for PCa, and validate its independent contribution to risk stratification in several radical prostatectomy (RP) patient cohorts.
INTRODUCTION
Cancer of the prostate (PCa) is the second leading cause of cancer death in male Americans. The clinical behavior of PCa is variable, and while the majority of PCa cases remain indolent, 10% of patients progress with aggressive metastatic disease and subsequent emergence of therapy-resistant PCa (1, 2) . In current practice, clinical variables including Gleason score, tumor stage, and PSA levels are used at the time of diagnosis to predict disease outcome (3, 4) . However, these prognostic factors have limitations, resulting in significant rates of overtreatment, with associated comorbidities (5) (6) (7) , and undertreatment, leading to disease progression and increased risk of PCaspecific mortality (8) (9) (10) .
The clinical heterogeneity of PCa reflects, in part, a remarkable genomic heterogeneity (11) (12) (13) (14) (15) (16) (17) (18) . This suggests that disease stratification based on molecular features may be of prognostic value beyond standard clinicopathological variables, and aid in the clinical management of the disease, as is the case for other cancers, i.e. breast (19) (20) (21) .
Currently, several tissue-based molecular tests offer prognostic information for patients with PCa either before or after treatment. These are based on general features of malignancy, such as the Prolaris test (initially described by Cuzick et al. (22) ), which incorporates information from 31 cell-cycle related genes, or on molecular features more specific for PCa (Decipher, Oncotype DX, ProMark, and ConfirmMDx tests (23) (24) (25) (26) (27) ). In addition, recent work has outlined the existence of several molecular subtypes of PCa (28) (29) (30) (31) . Notably, in one of these studies, the molecular subtypes were defined by specific driver mutations or gene fusions that are essentially mutually exclusive and that were able to categorize up to 74% of the analyzed tumors (32) . If shown to correlate with clinical behavior, these molecular subtypes could prove critical for the management and treatment of the disease. However, currently their prognostic value is not fully established, and a significant fraction of primary prostate cancers in the study, could not be categorized within these molecular subsets suggesting the existence of additional relevant molecular alterations.
High levels of variability in gene expression between tumors can be useful in identifying prostate and other cancers risk genes (33) . We hypothesized that molecular subtypes of primary prostate cancers may exist that have gene expression patterns associated with changes in the expression of these highly variable genes. A recent report lists TMEFF2 as one of the top 100 mRNA transcripts with the highest levels of inter-tumor variability in primary PCa tissues (34) . TMEFF2 is an androgen regulated transmembrane protein mainly restricted to brain and prostate. Our studies in PCa demonstrate a role of TMEFF2 as a tumor suppressor (35) (36) (37) (38) . Furthermore, studies using limited numbers of clinical samples, reveal changes in the expression of Tmeff2 with disease stage in PCa (39, 40) and gliomas (41) , supporting an important role of Tmeff2 in these diseases.
We have investigated the expression pattern of TMEFF2 in human prostate tissues and explored the potential of a TMEFF2 associated gene signature as a biomarker for disease prognosis. We report that low TMEFF2 mRNA expression is associated with decreased disease free survival (DFS) in the MSKCC PCa dataset. Using transcriptional profiling of cell lines and publically available PCa clinical data, we have identified a low TMEFF2 driven gene signature associated with poor clinical outcome, comprised of cell cycle related genes with increased gene expression. This study not only provides new insights into the clinical relevance of Tmeff2 in cancer, but also specifies a group of cell cycle related proteins as prognostic and potential therapeutic targets. 
METHODS

TMEFF2 Expression data
Validation cohorts
Four prostate cancer cohorts were used in this study to establish the prognostic value of the TMCC11 signature: MSKCC (46) (GSE21032); Cambridge (34) (GSE70768) and Stockholm (34) (GSE70769), are microarray datasets, and the TCGA PRAD (http://cancergenome.nih.gov/), an RNA sequencing cohort. Cancer samples for all cohorts were from RP specimens. Biochemical recurrence (MSCKK, Cambridge and Stockholm) or recurrence/progression (TCGA-PRAD) was the follow-up endpoint.
Clinical, histopathological data and summary of the cohorts are listed in Tables 1 and S1 (Additional File 1).
Mammalian cell culture and treatment.
The LNCaP and 22Rv1 cell lines were purchased from American Type Culture Collection (ATCC; Manassas, VA) and cultured as recommended. DHT (Sigma, Burlington ,MA) was used at a concentration of 10nM. For TMEFF2 knockdown, LNCaP and 22Rv1 cells were transduced with pLKO.1 lentiviral vectors with antisense TMEFF2 sequences shTMEFF2-0 (TRCN0000073518), shTMEFF2-1 (TRCN0000073519) and shTMEFF2-2 (TRCN0000073521). See table S2 in Additional File 1 for sequences.
RNA extraction and RNA-Seq
LNCaP cell expressing sh_TMEFF2 or the sh_scramble control were grown for 24 hrs in hormone-depleted media and stimulated with 10 nM DHT (or ethanol as vehicle control) for 24 hrs prior to harvesting for RNA extraction. Three biological replicates per sample were used. Total RNA was extracted with RNeasy mini kit (Qiagen, Waltham, MA) and cDNA was synthesized with SuperScript III First-Strand synthesis system (Life Technologies Inc, Carlsbad, CA). RNA integrity and quantity was assessed using the Agilent Bioanalyzer (Agilent Technologies, Santa Clara, CA). Raw 75bp paired-end sequences were generated from an Illumina NextSeq 500 sequencer (Illumina, San Diego, CA). Sequenced reads first underwent quality control with the FASTQC tool and then aligned to a contaminant genome to filter out reads which align to human ribosomal RNA, poly-A, poly-C, phiX virus or mitochondrial DNA sequence. The filtered reads were trimmed using Trimmomatic (47) , as well as read clipping based on quality over a sliding window, retaining reads with a minimum length of 15 bp. Trimmed, filtered reads were pseudoaligned to the GRCh38 human reference transcriptome using kallisto version 
Real-time polymerase chain reaction (RT-PCR)
Total RNA was extracted with RNeasy mini kit and cDNA was synthesized with iScript™ Reverse Transcription Supermix for RT-qPCR (BioRad, Hercules, CA). Quantitative RT-PCR was performed using the SsoAdvanced™ Universal SYBR® Greenand gene specific primers (see Table S2 , Additional File 1) on the Biorad CFX96™ Touch Real-Time PCR Detection System (BioRad, Hercules, CA). All RT-PCR experiments were performed under MIQE guidelines, using three biological replicates and two technical replicates.
Western blotting
Cell lysates were prepared in RIPA buffer containing a protease inhibitor mixture and analyzed by Western blot as described before (38) , using the following antibodies: TMEFF2 (HPA015587, Sigma) at a 1:1000 dilution; AR (sc-7305, Santa Cruz Biotechnology Inc, Dallas, TX) at a 1:1000 dilution; and Calnexin (ab22595; Abcam, San Francisco, CA) at a dilution of 1:4000.
TMCC11 signature selection process
From the 25 genes initially identified as significantly upregulated (Log2 fold change ≥1.8, ≤3.1; FDR < 0.05) by DHT in the LNCaP-TMEFF2 knockdown cells, we selected the 21 top-ranking upregulated genes (Log2 fold change ≥2.0) (refer to figure S2 in additional file 1). We interrogated this 21 gene subset in the MSKCC dataset (n = 150) in cBioPortal (51, 52) and selected those genes (n=11; TMCC11) whose expression was upregulated in patients with low TMEFF2 mRNA expression (at least 4 of those patients) and that maintain a strong functional association as demonstrated using STRING (53) and IPA pathway analyses (additional file 1; Figure S2 and S3). Two other signatures were used for SigCheck analysis. The TMCC13 is a modified TMCC11 signature including two additional genes, E2F7 and GSG2 (from the TMEFF2 21 top-ranking upregulated genes; additional file 1; Figure S3 ), selected based on their individual prognostic values and lack of overlap with genes from the Cuzick (22) signature. TMCC3 consist of the CDC45, NCAPG and CLSPN genes and was selected from TMCC11 as the optimal subset in predicting time to BCR in the Stockholm dataset. For this purpose, the dependence of time to BCR on the signature gene expression was modeled using GLM cox regression, and the search for the best subset relied on elastic net regularization, a standard features selection procedure implemented in the R package glmnet.
TMCC11 signature score development
Patients were divided in two categories (high and low) based on the TMCC11 gene signature, by calculating the mean expression over all the genes in the signature for each sample. The distribution for the population was calculated, and samples were included in the high group when their mean fell within the upper tertile (above the 67 th percentile) and in the low group when below the 67th percentile. 
Databases and statistics
Gene signature analysis with SigCheck
We analyzed the prognostic potential and specificity of the TMCC11 signature using the Bioconductor package SigCheck (55) . This software allows comparison of a gene signature prognostic performance against random and known gene signatures. In a first analysis, we compared the prognostic power of the TMCC11 gene signature and a total of 253 oncogenic signatures available from literature. The prognostic power of a gene signature was quantified by the log-rank test p-value for the difference between the time to BCR in high versus low risk groups according to overall signature gene expression. Mean expression over all the genes in the signature for each sample was computed and high versus low expression was considered as over or below the 67th percentile respectively. Log-rank P-values for each signature were computed using the Stockholm13 (GSE70769), Cambridge13 (GSE70768) and MSKCC14 (GSE21034) datasets downloaded from the GEO website. In a second analysis, we comparatively assessed the superiority of the TMCC11 and the other 253 oncogenic signatures against randomly constructed predictors. For each signature under study, 10,000 signatures of the same number genes were selected at random and for each log-rank p-value scores of their predictive power were computed as described above. A bootstrap p-value was then determined as the proportion of random gene signatures scoring better than the original gene signature. Stockholm, Cambridge and MSKCC datasets were also used for this analysis. The code for the analysis is available upon request.
RESULTS
Low expression of TMEFF2 is associated with advanced disease and is prognostic of clinical outcome
The previously described cell growth inhibitory function of TMEFF2 in PCa (35) (36) (37) led us to determine the relationship of Tmeff2 expression alterations to the clinicopathologic features of PCa. We first analyzed tumor associated changes in TMEFF2 expression by immunohistochemistry in PCa tissues ( Figure S1A , additional file 1). TMEFF2 expression was higher in patients with localized disease as compared to non-tumor samples (not shown). However, when patients were stratified by tumor stage, TMEFF2 expression was significantly decreased in more advanced pathological stages (Figure S1B, additional file 1).
We then used Oncomine (42) to examine alterations of TMEFF2 mRNA expression in publically available samples from PCa patients. Expression of TMEFF2 mRNA is significantly increased in the primary tumors of patients with PCa when compared to normal tissue, in multiple independent datasets ( Figure 1A ). However, in samples from metastases and castration resistant prostate cancer (CRPC), the levels of TMEFF2 mRNA are either unchanged or decreased compared to normal prostate, and significantly decreased (P<0.05) when compared to primary tumors ( Figure 1A) . These data suggest a negative correlation between TMEFF2 mRNA expression and progression to the advanced stages of PCa.
Based on these observations, we analyzed the prognostic value of TMEFF2 mRNA expression in the MSKCC dataset ((46); Table 1 ), a publically available human PCa dataset with clinical outcome data. Kaplan-Meier analysis demonstrated a significant (p<0.0001) correlation between TMEFF2 levels and disease progression (assessed by biochemical recurrence, BCR). Patients with the lowest TMEFF2 mRNA expression had higher BCR (20 vs. 110 months; Figure 1B ). These findings underscore the clinical significance of Tmeff2 in cancer.
TMEFF2 silencing in the LNCaP cell line increases androgen-driven expression of a group of cell-cycle related genes
TMEFF2 is one of the top 100 mRNA transcripts with the highest levels of inter-tumor variability in patient samples from several publically available datasets ((34) and Table S1 Additional File 3). Such heterogeneity and the fact that low TMEFF2 mRNA expression correlates with advanced disease, suggest that it may define a molecular signature with prognostic value. To begin understanding the molecular consequences of decreased TMEFF2 expression and its potential to define a prognostic gene signature, we conducted TMEFF2-targeted RNA interference experiments. We found that TMEFF2 silencing alters expression of androgen receptor (AR) targets, suggesting that previously reported TMEFF2 effects on growth (37) may be driven, in part, by TMEFF2-modulated ARmediated expression of genes involved in cell cycle related processes. Using shRNA, we silenced expression of TMEFF2 in LNCaP cells (Figure 2A , and additional file 1, figure   S2A and S2B), a PCa cell line that expresses high levels of TMEFF2 mRNA and protein.
Using RNA-Seq, we identified a group of 25 nuclear genes that were moderately but significantly upregulated, in the context of TMEFF2 silencing (Log2 fold change ≥1.8, ≤3.1; FDR < 0.05), by dihydrotestosterone (DHT) in the LNCaP-Tmeff2 knockdown cells as compared to control cells (transduced with scramble shRNA; Additional file1, Figure   S2C ). STRING pathway analysis (53) suggests that most of these genes are functionally associated (Additional file 1, Figure S2D ) and belong to the DNA replication and cell cycle gene ontology categories.
Out of the initial group of genes, we selected 11 (Additional file 1, Figure S3 and methods) referred to as the "TMEFF2 modulated cell cycle 11 (TMCC11)" gene signature. qRT-
PCR analysis in LNCaP cells confirmed that DHT mediated induction of the TMCC11
genes was significantly increased in LNCaP cells in which TMEFF2 expression was low compared to control cells ( Figure 2B ). High expression of these genes with low TMEFF2 expression was also seen in patients samples from the MSKCC dataset (Additional file 1, Figure S3C ). Clustering analysis of the TMCC11 signature genes in the MSKCC dataset indicate that expression of these genes is highly correlated ( Figure 2C ). These 11 genes are all tightly related to cell-cycle and DNA replication and repair processes (Additional file 1, Figure S3B ). Moreover, silencing of TMEFF2 in PCa cells affects cell cycle progression (Additional file 1, Figure S4 ) supporting the role of TMEFF2 in modulating expression of cell-cycle related genes.
In clinical samples from the Grasso (45) and MSKCC (46) datasets, the expression of the individual genes from the TMCC11 signature is significantly increased in CRPC and metastatic disease samples when compared to normal tissue, and inversely correlated with the expression of TMEFF2 in the same samples (Additional file 1, Figure S5A and S5B). In addition, mRNA coexpression analysis using the PCa MSKCC and PRAD TCGA datasets indicates that these genes are significantly co-expressed (Additional file 1, Figure S6 ).
The TMEFF2-modulated gene signature is an independent marker of recurrence after prostatectomy in multiple clinical datasets
Based on our results suggesting that loss of TMEFF2 often predates aggressive/metastatic disease, we postulated that the TMEFF2-modulated TMCC11 gene signature could have prognostic value. We evaluated this hypothesis using BCR as the clinical endpoint in the PCa MSKCC dataset (46) ( Table 1, and Additional file 1, Table   S1 and Figure S7 , provide information on the samples). The MSKCC dataset includes a number of prostatectomy samples from patients with wide range of times to BCR as measured by increased levels of PSA. Individually, increased expression of each of the genes comprising TMCC11 was statistically significant (P< 0.01) in predicting BCR (Additional File 1, Table S4 ; for CLSPN p =0.0137). In Kaplan-Meier analyses, high expression of the TMCC11 signature was associated with a median time to progression of 55.39 months vs. greater than 150 months for patients with low expression of TMCC11 (log-rank P value = 1.11e-05; Figure 3A) . These results indicate that the TMCC11 signature is a powerful predictor of aggressive PCa, segregating the tumors into high and low-risk groups based on time to BCR. We obtained similar results using the SurvExpress (54) database for analysis (Additional File 1, Figure S8 ).
In Cox regression analyses, TMCC11 was a significant prognostic variable (p<0.001) with a hazard ratio (HR) of 4.1 ( Table 2 ). In multivariate analysis, and a model constructed using a forward stepwise selection process coupled with Cox proportional hazard, TMCC11 remained a significant prognostic variable with a HR of 2.27 and 2.35 respectively ( Table 2 ). The final model also selected pathological T-score and surgical Gleason score as significant predictors of BCR (Table 2) .
We validated the prognostic findings in additional independent publically available datasets (see Table 1 , Additional File 1, Table S1 and Figure S7 demonstrate that the TMCC11 signature is an independent predictor of recurrence after prostatectomy in these datasets ( Table 2) . Taken together, these data suggest that the TMCC11 signature is prognostic for risk of disease recurrence after radical prostatectomy, and has an added benefit in the context of standard clinical variables in several independent datasets.
The prognostic value of the TMCC11 signature was further evident using C-statistics (Additional File 1, Table S5 ). The TMCC11 signature was a significant predictor across all datasets. In the TCGA-PRAD, it performed better (C-index, 0.64; confidence interval, 0.58-0.70; p<0.001) than Gleason (C-index, 0.62; confidence interval, 0.58-0.67; p<0.001) or pathological score (C-index, 0.61; confidence interval, 0.57-0.66; p<0.001).
Moreover, in all the datasets, the TMCC11 signature significantly improved prognostic ability when combined with other clinical variables (Additional File 1, Table S5 ). The persistence of the interaction terms as significant effects proves that the TMCC11 predictive effectiveness might vary with the levels of the other clinical variables.
In selected patients from the MSKCC and TCGA-PRAD datasets with high pathological T (≥ T3) or Gleason (≥ 4+3) scores, high TMCC11 significantly stratified men at risk for disease recurrence/progression (Additional File 1, Figures S9 and S10 ). TMCC11 provides prognostic information in high-risk patients beyond that provided by established clinico-pathological prognostic features as demonstrated using multivariate analysis (Additional File 1, Tables in figures S9 and S10). These results suggest that TMCC11 has prognostic value in men with high-grade tumors, after RP. TMCC11 failed to stratify patients with low surgical Gleason score, however, preliminary data using the MSKCC (46) and Stockholm (34) datasets indicate that TMCC11 can stratify patients presenting with low biopsy Gleason score, suggesting that the signature may be informative for PCa management after a positive biopsy (Additional File 1, Figure S11 ).
Prognostic assessment of the TMCC11 gene signature
Several gene signatures have predictive capabilities in PCa. We therefore conducted additional tests to determine the value of the TMCC11 signature when compared to other signatures, using the Bioconductor package SigCheck (55) . This software allows comparison of a gene signature prognostic performance against random and known gene signatures. Initially, we analyzed the prognostic power (based on time to recurrence) of TMCC11 and other previously identified oncogenic signatures: 6 signatures for PCa (22, 25, 34, (56) (57) (58) , 189 oncogenic signatures from multiple cancer types in MSigDB, and 48 breast oncogenic signatures (compiled in (59)) (n=243, Tables 3 and Additional File 1,   Table S6 ). TMCC11 outperformed most signatures (Additional File 1, Table S6 ).
Considering just the six PCa gene signatures (Table 3) , only the Cuzick (n=31) signature achieved comparable performance to the TMCC11 across the three datasets for identifying patients with shorter time to biochemical relapse, and the performance depended on the dataset utilized. Of note, 5 genes within the Cuzick set overlap with the TMCC11 set. We obtained similar results using two other TMCC11 derived signatures, TMCC13 and TMCC3 (Table S6 Additional File 1). TMCC13 is a modified form of TMCC11 including two additional genes, E2F7 and GSG2, while TMCC3 consisted of only 3 from the TMCC11 signature that do not overlap with the Cuzick signature. These results underscore the independent prognostic value of the genes included in the TMCC11 signature.
We then analyzed the performance of the oncogenic signatures against 10,000 signatures consisting of the same number of genes (for the specified signature) selected at random (Tables 3 and Additional File 1, Table S7 ). The TMCC11 signature performed in the 97 th and 99 th percentiles, with only 3%, 1.2% and 0.18% of the random signatures demonstrating an equal or smaller p-value (empirical p-values of p=0.0305, p=0.012 and p=0.0018) in predicting relapse in the Stockholm, Cambridge and MSKCC datasets respectively. Considering the PCa signatures, only the Cuzick (n=31) signature achieved comparable performance to the TMCC11 across the three datasets (Table 3 ). TMCC11, TMCC13 and TMCC3 outperformed most of the oncogenic signatures described above (n=243), when tested against random signatures (Table S7 Additional File 1).
DISCUSSION
Here, we have identified an 11-gene prognostic signature (TMCC11) for PCa progression consisting of genes associated with cell-cycle and DNA damage response. The prognostic value of this signature was confirmed on several publically available cohorts totaling 834 samples from geographically different cohorts of patients that underwent RP.
TMCC11 is an independent predictor of biochemical recurrence after RP and added significant prognostic value to standard clinicopathological variables. In multivariate analysis TMCC11 was the only variable consistently predictive of disease recurrence in all of the datasets, and it significantly increased risk prediction over other clinical variables and when combined with other variables (Tables 2 and Additional File S5) . Moreover, in subsets of patients with high Gleason or pathological scores, the TMCC11 signature provided a statistically significant stratification of patients identifying high and low risk groups of BCR, and preliminary data suggests that TMCC11 can stratify patients that present with low biopsy or pre-operative Gleason scores. All together, these results suggest that TMCC11 may provide relevant prognostic information in several clinical scenarios and have an impact not only on the decision of whether to provide adjuvant therapy after RP, but also on treatment management after a positive biopsy.
Genomic and transcriptomic analyses have provided insight into the complexity of prostate tumors and the existence of molecular subtypes. However, the clinical applicability of these classifications has been thwarted, due in part to the highly heterogeneous nature of PCa and the difficulty of identifying additional relevant alterations that occur at low frequencies (11) (12) (13) (14) (15) (16) (17) (18) (60) . We hypothesized that heterogeneously expressed genes can expose unidentified molecular subclasses of PCa and/or identify translationally relevant gene sets. Expression of Tmeff2, an androgen regulated gene, is highly variable across several different PCa datasets ((34) and Table   S3 , Additional File 1). Low TMEFF2 expression significantly associated with shorter time to post-RP BCR. Although the prognostic value of low TMEFF2 mRNA levels is uncertain, low TMEFF2 mRNA correlates with increased androgen response of the cell cycle genes that define the TMCC11 signature in cell lines, and increased mRNA levels of the same genes in clinical datasets. Interestingly, SPINK1 also demonstrates highly variable expression across the same datasets (Additional File 1, Table S3 ). SPINK1 is an androgen-regulated gene highly overexpressed in approximately 10% of PCa cases (61) (62) (63) . While the prognostic role of SPINK1 for PCa is unclear (64), it has been suggested that pathways downstream of SPINK1 may have translational and prognostic significance (64, 65) . These observations hint to highly variably expressed genes as a potential source of information with translational value.
Currently several tissue-based genomic biomarkers offer prognostic information for patients with PCa either before or after treatment (23) . The Decipher™ (24) , Oncotype DX® (25) and Prolaris® (22) are commercially available panels based on measurement of gene expression changes at the RNA level. The Prolaris® panel, based on the set described in Cuzick (22) , examines the expression of 31 genes involved in cell cycle progression and 5 out of the 11 genes in TMCC11 are common to this panel. We observed a similar prognostic performance for the Cuzick (22) and the TMCC11 signatures when compared against random size-matched signatures. In addition, the prognostic power (based on p-value) of our signature vs. Cuzick (22) was dependent on the dataset utilized, but they were similarly informative and both behaved as strong risk predictors. While these comparisons need to be verified in independent studies, TMCC11
represents a smaller and more focused distinct gene set with potentially added value in specific patient subsets. The smaller size of the TMCC11 signature (11 genes vs. 31 of Cuzick (22) ) is an advantage in clinical use since smaller signatures are more amenable to testing with reduced RNA quantities (i.e. biopsy samples) or even assayed with immunohistochemistry. In addition, TMCC3, a signature consisting of three genes selected from the TMCC11 signature, and that does not overlap with the Cuzick gene set, demonstrated excellent prognostic ability in SigCheck analysis. This suggests that subsets of the TMCC11 genes can be of prognostic value. Finally, the fact that our studies have independently led to the identification of a cell-cycle based signature validates the results and points to the value of using cell cycle genes as prognostic markers in PCa.
CONCLUSIONS
Using an unconventional approach, we have identified an 11-gene signature consisting of functionally related nuclear genes with roles in DNA replication/ repair and/or cell cycle that can improve accuracy of prognosis in patients with PCa after RP in the context of current clinicopathological variables. Prognostic gene signatures containing, or based on, cell cycle gene expression changes have been identified using other approaches and different sample types. This observation not only validates our results, but also suggests that heterogeneity may lead to similar cellular consequences, providing cell cycle based signatures with rather global predictive values. The TMCC11 signature requires further validation in multi-institutional cohorts and clinical trials. In addition, the ability of TMCC11 to provide prognostic information using biopsy samples needs to be further explored. 
